SPDR S&P 500 (SPY)

[Canna_Business]

The potential reclassification of cannabis by the DEA, removing it from the schedule-1 drugs list, could significantly impact both medical research and patient access. By allowing the FDA to thoroughly study cannabis for its medical applications, we could see more evidence-based treatments emerge. Additionally, this change could pave the way for insurance companies to include medical cannabis in their coverage, potentially reducing costs for patients through co-pay systems akin to those used for traditional prescription medications. This shift could make medical cannabis more accessible and affordable for those who need it.